ALCAM

ALCAM Molekülinformation

Englischer Name	Activated leukocyte cell adhesion molecule	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1	Target-Alias	CD166 antigen，Activated leukocyte cell adhesion molecule，CD166，ALCAM，MEMD，Activated Leucocyte Cell Adhesion Molecule，Activated-Leukocyte Cell Adhesion Molecule
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Activated leukocyte cell adhesion molecule
Target-Alias	CD166 antigen，Activated leukocyte cell adhesion molecule，CD166，ALCAM，MEMD，Activated Leucocyte Cell Adhesion Molecule，Activated-Leukocyte Cell Adhesion Molecule
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

ALCAM Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (2)
Etikett
Fc Tag (1)His Tag (1)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
CD6-H5228	Human	HEK293	Human ALCAM Protein, His Tag				In den Warenkorb legen
CD6-H5259	Human	HEK293	Human ALCAM Protein, Fc Tag				In den Warenkorb legen

Gesamtmenge2

ALCAM Molekülhintergrund

CD166 antigen is a 100-105 kD typeI transmembrane glycoprotein that is a member of the immunoglobulin superfamily of proteins, which is also known as Activated leukocyte cell adhesion molecule (ALCAM) in human, SC-1/DM-GRASP/BEN in the chicken, and KG-CAM in the rat. CD166 is a cell adhesion molecule that binds to CD6. CD166 involved in neurite extension by neurons via heterophilic and homophilic interactions.

ALCAM Molekülalias

CD166,ALCAM,CD6L,KG-CAM,MEMD

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Praluzatamab ravtansine	CX-2009	Phase 2 Clinical	Cytomx Therapeutics Inc, Immunogen Inc	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms	Details